These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 33688649)

  • 1. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.
    Ndeupen S; Qin Z; Jacobsen S; Estanbouli H; Bouteau A; Igyártó BZ
    bioRxiv; 2021 Jul; ():. PubMed ID: 33688649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.
    Ndeupen S; Qin Z; Jacobsen S; Bouteau A; Estanbouli H; Igyártó BZ
    iScience; 2021 Dec; 24(12):103479. PubMed ID: 34841223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.
    Qin Z; Bouteau A; Herbst C; Igyártó BZ
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.
    Qin Z; Bouteau A; Herbst C; Igyártó BZ
    PLoS Pathog; 2022 Sep; 18(9):e1010830. PubMed ID: 36054264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
    Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
    Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses.
    Ndeupen S; Bouteau A; Herbst C; Qin Z; Hutchins Z; Kurup D; Diba LZ; Igyártó BZ
    bioRxiv; 2021 Aug; ():. PubMed ID: 34373854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2.
    Mao S; Li S; Zhang Y; Long L; Peng J; Cao Y; Mao JZ; Qi X; Xin Q; San G; Ding J; Jiang J; Bai X; Wang Q; Xu P; Xia H; Lu L; Xie L; Kong D; Zhu S; Xu W
    Nano Today; 2023 Feb; 48():101730. PubMed ID: 36570700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque.
    Naderi Sohi A; Kiani J; Arefian E; Khosrojerdi A; Fekrirad Z; Ghaemi S; Zim MK; Jalili A; Bostanshirin N; Soleimani M
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic Endothelial Cells Produce Chemokines in Response to the Lipid Nanoparticles Used in RNA Vaccines.
    Liu Y; Suzuoki M; Tanaka H; Sakurai Y; Hatakeyama H; Akita H
    Biol Pharm Bull; 2024; 47(3):698-707. PubMed ID: 38538323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.
    Swaminathan G; Thoryk EA; Cox KS; Meschino S; Dubey SA; Vora KA; Celano R; Gindy M; Casimiro DR; Bett AJ
    Vaccine; 2016 Jan; 34(1):110-9. PubMed ID: 26555351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety.
    Bae SH; Yoo S; Lee J; Park HJ; Kwon SP; Jin H; Park SI; Lee YS; Bang YJ; Roh G; Lee S; Youn SB; Kim IW; Oh HR; El-Damasy AK; Keum G; Kim H; Youn H; Nam JH; Bang EK
    Bioact Mater; 2024 Aug; 38():486-498. PubMed ID: 38779592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE).
    Parhiz H; Brenner JS; Patel PN; Papp TE; Shahnawaz H; Li Q; Shi R; Zamora ME; Yadegari A; Marcos-Contreras OA; Natesan A; Pardi N; Shuvaev VV; Kiseleva R; Myerson JW; Uhler T; Riley RS; Han X; Mitchell MJ; Lam K; Heyes J; Weissman D; Muzykantov VR
    J Control Release; 2022 Apr; 344():50-61. PubMed ID: 34953981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
    Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
    Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.
    Lutz J; Lazzaro S; Habbeddine M; Schmidt KE; Baumhof P; Mui BL; Tam YK; Madden TD; Hope MJ; Heidenreich R; Fotin-Mleczek M
    NPJ Vaccines; 2017; 2():29. PubMed ID: 29263884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
    Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
    Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
    Shepherd SJ; Han X; Mukalel AJ; El-Mayta R; Thatte AS; Wu J; Padilla MS; Alameh MG; Srikumar N; Lee D; Weissman D; Issadore D; Mitchell MJ
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303567120. PubMed ID: 37556502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.